Loading
Standard Diet / Obesity / Overweight · Interventional Study
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered clinical trial currently recruiting participants to examine effects of nicotinamide riboside supplementation and ketogenic diet on energy expenditure and fat oxidation in overweight/obese adults and those with MODY2 diabetes. No results are yet available; the registry entry describes only the planned study design and primary outcome measures.
Interventional, Randomized, Crossover, Double masking, Basic Science purpose. Overweight, Obesity; age from 18 Years; to 65 Years. Intervention: Men with overweight or obesity; MODY2 Patients; Women with overweight or obesity. Compared with: Placebo (identical-appearing pill with no nicotinamide riboside) during the alternative clinic stay in healthy volunteers; standard American diet as baseline before ketogenic diet.. n = 100. 1 site: United States.
This is a registered clinical trial currently recruiting participants to examine effects of nicotinamide riboside supplementation and ketogenic diet on energy expenditure and fat oxidation in overweight/obese adults and those with MODY2 diabetes. No results are yet available; the registry entry describes only the planned study design and primary outcome measures.
No data on effect sizes, comparisons, or safety events are available.
Results from this study, when available, may inform whether nicotinamide riboside enhances the metabolic benefits of ketogenic diet for managing fatty liver disease and optimizing fat oxidation in overweight and metabolically compromised populations.
This is a clinical trial registration with no results posted; it describes a planned interventional study in an early recruitment phase testing nicotinamide riboside and ketogenic diet on metabolic outcomes in overweight/obese adults and those with MODY2 diabetes.
As stated by the source record.
Quoted from the source exactly as published.
Results from this study, when available, may inform whether nicotinamide riboside enhances the metabolic benefits of ketogenic diet for managing fatty liver disease and optimizing fat oxidation in overweight and metabolically compromised populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06044935). This is a study registration, not published results. Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 100 participants (ESTIMATED). Conditions: Overweight, Obesity. Interventions: OTHER: Standard Diet; OTHER: Ketogenic Diet; DIETARY_SUPPLEMENT: Placebo; DIETARY_SUPPLEMENT: Nicotinamide Riboside. Primary outcome measures: Mean change in sleeping energy expenditure between the ketogenic diet and the baseline run-in diet , 7 days; Mean difference in sleeping energy expenditure between NR and placebo during the ketogenic diet , 5 days. Brief summary: Background: At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem. Objective: To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat. Eligibility: Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults with maturity-onset diabetes of the young type 2 (MODY2) are also needed. Design: Participants with diabetes will have 1 screening visit and a 9-day clinic stay. Healthy volunteers will have 1 screening visit and 2 clinic stays of 1 to 2 weeks each. During screening, all participants will have a physical exam with blood and urine tests. They will have their heart rhythm measured while riding a gym bike. NR is a pill taken by mouth. Only healthy volunteers will take the NR, for 14 days at a time, during 1 clinic stay. During their other stay, they will take placebos; these are pills that look like the study supplement but contain no NR. During each clinic stay, all participants will eat a normal American diet. Then they will eat a ketogenic "low-carb" diet for 5 days. Participants will have many tests, including: Sleeping every night and having two 24-hour stays in a special room that measures the gases their body uses and produces. Drinking a high-fat shake, then remaining seated for 5 hours while their blood and breath are monitored. Having a substance injected into the arm and remaining seated for 3 hours while their blood is measured. Wearing monitors to measure their activity levels. Another monitor will measure their blood glucose levels. Having imaging scans. ...
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.